Leadership

Neuromod's leadership team comprises dedicated biomedical engineers, clinical scientists, surgeons and audiologists who are experienced in the research and development of neuromodulation devices and tinnitus diagnosis and treatment. The team is dedicated to the advancement of clinical research and technology development in neuromodulation for chronic tinnitus.

Chief Executive Officer / Founder

Dr. Ross O’Neill PhD MBA
Chief Executive Officer / Founder

Ross O’Neill is the Founder and CEO of Neuromod™. Ross earned a PhD from Maynooth University and an MBA from Trinity College Dublin. In 2010, Ross founded Neuromod™ to research, develop and commercialise a tinnitus treatment technology developed in Maynooth University. In the same year, Ross was awarded the Enterprise Ireland ‘One to Watch’ Award and was named one of Science Foundation Ireland’s ‘Rising Stars’. Since then, he has successfully led Neuromod through multiple financing rounds, including €2.7M in Seed Capital and a €5.5M Series-A with Fountain Healthcare Partners. Ross successfully delivered the ISO 13485 accreditation of the Neuromod’s quality management system and European regulatory approval of the company’s mutebutton® bi-modal neuromodulation device. He secured critical partnerships for Neuromod™, including an S&P500-listed manufacturing partner.  In 2014, Neuromod was awarded the Irish Medical Device Association (IMDA) ‘Emerging Company of the Year’, as voted by global leaders in the medical device industry, in recognition of these achievements.

 

Chief Medical Officer

Mr. Brendan Conlon - ENT
Chief Medical Officer

Mr. Brendan Conlon is a leading ear, nose and throat surgeon with over 20 years of experience in the areas of vestibulocochlear dysfunction and disease, including hearing loss and tinnitus. Brendan has conducted research into the pathogenesis of sensorineural hearing loss and cochlear dysfunction in animal models in leading US and European university hospitals, including Duke, University of Bordeaux, Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin. Brendan brings a unique insight into the requirements and challenges of developing medical technologies for the public and private healthcare systems.

Chief Technology Officer

Mr. Stephen Hughes - BE
Chief Technology Officer

Mr. Stephen Hughes is a highly accomplished Electronic Design Engineer with over 20 years of experience in bringing complex designs from conception through to production. Stephen is highly experienced in designing and testing to meet IEC 60601-1, ISO 10993 and 14971 medical safety standards. He has extensive audio digital signal processing and embedded programming experience and has researched, developed and manufactured technologies for Nokia, Intel, GN Resound, Massachusetts Institute of Technology (MIT) and the University of Glasgow.

Chief Financial Officer

Mr. Derek Madden - CPA CTax
Chief Financial Officer

Mr. Derek Madden is a certified accountant and tax advisor with over 20 years of experience in auditing and advisory services. Prior to joining Neuromod in 2012, Derek was the founding partner of a thriving accountancy practice that provided tax planning, auditing and other advisory services to Irish small and medium enterprises across a range of industries.

Director

Dr. Manus Rogan
Director

Dr Manus Rogan is a Managing Partner and co-founder of Fountain Healthcare Partners. He has over 27 years of investment and operating experience in the life science sector in both the US and Europe. Manus earned a PhD in chemistry from the University of York (sponsored by GlaxoSmithKline) and an MBA from Trinity College Dublin. Manus began his career in product development at GlaxoSmithkline in the UK and in 1996 joined Elan Corporation’s business development group. For four years he was responsible for licensing products and drug delivery technologies in Europe and Japan. In 2001, Manus joined Elan’s Corporate Venture Capital group in New York where he invested in private and public biotechnology companies. Investments included Sirna (acquired by Merck, 2006) and Beyond Genomics (IPO, 2011). In his 7 years at Elan, Manus concluded over twenty five investment and technology licensing transactions involving companies in the US, Europe and Japan. Manus led Fountain’s investment in Innocoll Inc. and currently serves on the board of Opsona Therapeutics, Mainstay Medical (IPO, 2014) and Neuromod Devices. He recently served as the Chairman of the Irish Venture Capital Association (‘IVCA’) and previously represented Fountain on the board of Amarin Corporation.

Director

Dr. Ross O'Neill - PhD MBA
Director

Dr. Ross O’Neill is the CEO and founder of Neuromod™ . Ross earned a PhD in biomedical engineering from Maynooth University and an MBA from Trinity College Dublin. He founded Neuromod™ in 2010 to research, develop and ultimately commercialise a tinnitus treatment technology developed by researchers in Maynooth University. Since then, he has successfully led Neuromod™ through multiple financing rounds, including €2.7M in Seed Capital and a €5.5M Series-A with Fountain Healthcare Partners. He delivered the design, implementation and ISO 13485 accreditation of the Neuromod’s quality management system and the design, manufacture and European regulatory approval of the company’s first product mutebutton®. He secured critical commercial partners for the company, including global distributors and S&P500-listed electronic manufacturers.